Andarix Pharmaceuticals' Targeted Therapy Reduced Tumors in Lung Cancer Study

    BOSTON, MA, May 26, 2017 /24-7PressRelease/ -- Andarix Pharmaceuticals, a clinical stage company, announced today the results of a phase 1/2 clinical study in lung and neuroendocrine cancer patients.

In an open label, single arm study, refractory lung cancer patients to standard of care therapy were identified by image analysis using Rhenium Re 188 P2045, a radiolabeled somatostatin analog. 25 Patients received the imaging dose of 10uCi of Re188 and 265ng of peptide by intravenous injection. Patients were selected based on high somatostatin (SSTR) expression levels to receive 30uCi of Re188 P2045 as a therapeutic dose 14 days after imaging. Patients were followed for 8 weeks post treatment.

The patients who received R188 P2045 at the therapeutic dose had a 25% reduction in tumor mass based on image analysis versus typical results of stable disease from standard of care.

The clinical findings from this recent study demonstrate the of the Tozaride therapy to reduce tumor burden in patients who are typically resistant to standard of care in lung cancer. Andarix is expanding the clinical study in lung cancer patients to further support the therapeutic application of the Tozaride drug.

About Tozaride
Tozaride is a novel, best-in-class therapy for lung, pancreatic and other cancers based on a radio-labeled somatostatin peptide analogue. Early clinical studies of Tozaride demonstrated that it is well tolerated and may produce prolonged stable disease and improved overall survival in advanced lung cancer patients whose disease has continued to progress after failing other therapies. Tozaride targeted radiotherapy represents a new treatment paradigm which is expected to yield significant clinical benefit for both small cell lung cancer (SCLC), and non-small cell (NSCLC) patients, and which will provide another treatment option for patients who are not eligible for, or who have not responded to current therapies.

Andarix Pharmaceuticals is at the forefront of personalized therapies for cancer, developing both the imaging agents that can identify appropriate patients, as well as the targeted therapies for these patients. The company's products have progressed through early clinical development. The Andarix technology is based on a proprietary somatostatin peptide conjugate applicable to lung, pancreatic, neuroendocrine, and other cancers. Extensive research has demonstrated that somatostatin receptors are highly up-regulated on several solid tumors, particularly lung cancers. Pancreatic cancer is responsible for significant cancer mortality in the United States, with over 50,000 new diagnoses of pancreatic cancer and over 50,000 deaths attributable to this disease annually. To learn more about Andarix, please visit www.andarix.com.

# # #